CSF1R and neoplasm: In a phase‐II study of recurrent glioblastoma, PLX3397 treatment at a daily dose of 1000 mg showed acceptable tolerability and led to both CSF‐1R activity inhibition and TAMs infiltration reduction in tumor tissues.372